Alnylam Pharmaceuticals (ALNY) EBT Margin Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9,237.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 441.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -408.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 363.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 7,297.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,297.00 |
| Dec 31, 2025 | 6,965.00 |
| Sep 30, 2025 | 17,605.00 |
| Jun 30, 2025 | 11,761.00 |
| Mar 31, 2025 | 11,184.00 |
| Dec 31, 2024 | 6,798.00 |
| Sep 30, 2024 | 8,716.00 |
| Jun 30, 2024 | 8,370.00 |
| Mar 31, 2024 | 9,936.00 |
| Dec 31, 2023 | 11,762.00 |
| Sep 30, 2023 | 22,068.00 |
| Jun 30, 2023 | 8,510.00 |
| Mar 31, 2023 | 12,862.00 |
| Dec 31, 2022 | 32,406.00 |
| Sep 30, 2022 | 14,462.00 |
| Jun 30, 2022 | 36,653.00 |
| Mar 31, 2022 | 43,207.00 |
| Dec 31, 2021 | 90,288.00 |
| Sep 30, 2021 | 1.17 Mn |
| Jun 30, 2021 | 46,124.00 |